January 12, 2017
Wells Pharmacy Network, LLC, is voluntarily recalling 526 vials of Nandrolone Decanoate (H), 200 mg/mL Injectable, 10 mL vial, according to the US Food and Drug Administration (FDA) Enforcement Report for the week of January 11, 2017.
The recall began on September 21, 2016 and is one of many drugs recalled by Wells Pharmacy Network, LLC, due to a “lack of assurance of sterility.”
Nandrolone Decanoate is an anabolic steroid indicated for the management of anemia and renal insufficiency. It has also been shown to increase hemoglobin and red cell mass.
The affected products were distributed throughout the United States and include all lot codes prepared between February 2, 2016 and September 14, 2016. Known lot codes include: 04112016@16, 04282016@3, 05202016@6, 06132016@4, 07052016@1, 07272016@7.
The FDA has designated the recall a class II, indicating that exposure to the drug could cause temporary or medically reversible adverse health consequences, but is not likely to result in serious injury or death.—Sean McGuire
Enforcement Report. US Food and Drug Administration Website. http://www.accessdata.fda.gov/scripts/ires/index.cfm. Published January 11, 2017 Accessed January 12, 2017.